Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 6, 2005 - Issue 5
Submit an article Journal homepage
107
Views
3
CrossRef citations to date
0
Altmetric
Drug Evaluation

An evaluation of paroxetine in generalised social anxiety disorder

Michael Van AmeringenDepartment of Psychiatry and Behavioural Neurosciences McMaster University, Hamilton, OntarioCanada
,
Catherine ManciniAnxiety Disorders Clinic 3G Clinic, McMaster University Medical Centre, Hamilton Health Sciences, Main St. W, Hamilton, ON, L8N 3Z5Canada Tel: +1 905 521 5018; Fax: +1 905 521 2628;E-mail: [email protected]
,
Beth PattersonDepartment of Psychiatry and Behavioural Neurosciences McMaster University, Hamilton, OntarioCanada
&
Mark BennettAnxiety Disorders Clinic 3G Clinic, McMaster University Medical Centre, Hamilton Health Sciences, Main St. W, Hamilton, ON, L8N 3Z5Canada Tel: +1 905 521 5018; Fax: +1 905 521 2628;E-mail: [email protected]
Pages 819-830 | Published online: 10 May 2005

Bibliography

  • American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, 4th edn (1994). Washington DC: American Psychiatric Press, Washington DC, USA.
  • SCHNEIER FR, BLANCO C, ANTIA SX, LIEBOWITZ MR: The social anxiety spectrum: Psychiatr. Chit. North Am. (2002) 25(4):757–774.
  • KESSLER RC, MCGONAGLE KA, ZHAO S et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Arch. an. Psychiatry (1994) 51:8–19.
  • MATHEW SJ, COPLAN JD, GORMAN JM: Neurobiological mechanisms of social anxiety disorder. Am. I Psychiatry (2001) 158(10):1558–1567.
  • VAN AMERINGEN M, MANCINI C, FARVOLDEN P: The impact of anxiety disorders on educational achievement. Anxiety Disord (2003) 17:561–571.
  • KATZELNICK DJ, KOBAK KA, DELEIRE T: Impact of generalized social anxiety disorder in managed care. Am. J. Psychiatry (2001) 158(12):1999–2007.
  • MERIKANGAS KR, ANGST J: Comorbidity and social phobia: evidence from clinical, epidemiologic, and genetic studies. Eur. Arch. Psychiatry Chit. Neurosci. (1995) 244:297–303.
  • GELERNTER CS, UHE TW, CIMBOLIC P et al: Cognitive-behavioural and pharmacological treatment of social phobia: a controlled study. Arch. Gen. Psychiatry (1991) 48:938–945.
  • LIEBOWITZ MR, SCHNEIER P, CAMPEAS R et al.: Phenelzine vs. atenolol in social phobia: a placebo-controlled comparison. Arch. Gen. Psychiatry (1992) 49:290–300.
  • HEIMBERG RG, LIEBOWITZ MR, HOPE DA et al.: Cognitive behavioral group therapy vs. phenelzine therapy for social phobia: 12 week outcome. Arch. Gen. Psychiatry (1998) 55:1133–1141.
  • FALEN T, NILSSON HI, BORG K, HUMBLE M, PAULI U: Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. Acta. Psychiatr: Scand. (1995) 92:351–358.
  • VAN VLIET LM, DEN BOER JA, WESTENBERG HGM: Psychopharmacological treatment of social phobia: clinical and biological effects of brofaromine a selective MOA-A inhibitor. Eur. Neuropsychopharmacul (1992) 2:21–29.
  • VERSIANI M, NARDI AE, MUNDIM FD, PINTO S, SABOYA E, KOVACS R: The long-term treatment of social phobia with moclobemide. Int. Chit. Psychopharmacul (1996) 11 (Suppl. 3):83–88.
  • DAVIDSON JRT, POTTS NS, RICHICHI E et al.: Treatment of social phobia with clonazepam and placebo. Chit. Psychopharmacul (1993) 13:423–428.
  • VERISANI M, NARDI AE, FIGUERIA I, MENDLOWICZ, MARQUES C: Double-blind placebo-controlled study of bromazepam in social phobia: Serie psicofarmacologia-59. J. Bass Psiquitr. (1997) 46:167–171.
  • VAN VLIET IM, DEN BOER JA, WESTENBERG HG: Psychopharmacological treatment of social phobia; a double-blind placebo controlled study with fluvoxamine. Psychopharmacology (1994) 115(1-2):128–134.
  • STEIN MB, FYER AJ, DAVIDSON JR, POLLACK MH, WIITA B: Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am. J. Psychiatry (1995) 156(5):756–760.
  • DAVIDSON J, YARYURA-TOBIAS J, DUPONT R et al.: Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J. Clio. Psychopharmacul (2004) 24(2):118–125.
  • KATZELNICK DJ, KOBAK KA, GREIST JH, JEFFERSON JW, MANTLE JM, SERLIN RC: Sertraline for social phobia: a double-blind, placebo controlled crossover study. Am. J. Psychiatry (1995) 152(9):1368–1371.
  • VAN AMERINGEN MA, LANE KM, WALKER JR et al.: Sertraline treatment for generalized social phobia: a 20-week, double-blind, placebo controlled study. Am. J. Psychiatry (2001) 158(2):275–281.
  • BLOMOFF S, HAUG TT, HELLSTROM K et al.: Randomised controlled general practice trial of sertraline, exposure therapy, and combined treatment in generalized social phobia. BE I Psychiatry (2001) 179:23–30.
  • STEIN MB, LEIBOWITZ MR, LYDIARD RB, PITTS CD, BUSHNELL W, GERGEL I: Paroxetine treatment for generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. (1998) 280(8): 708–713.
  • BALDWIN D, BOBES J, STEIN DJ, SCHARWACHTER I, FAURE M: Paroxetine in social phobia/ social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br. J. Psychiatry (1999) 175:120–126.
  • DAVIDSON JRT: Pharmacotherapy of social anxiety disorder. J. Chit. Psychiatry (1998) 59:47–51.
  • ALLGULANDER C: Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr. Scand. (1999) 100(3):193–198.
  • ALLGULANDER C, MANGANO R, ZHANG J et al: Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum. Psychopharmacul Chit. Exp. (2004) 19:387–396.
  • PANDE AC, DAVIDSON JRT, JEFFERSON JW et al.: Treatment of gabapentin: a placebo-controlled study. Chit. Psychopharmacul (1999) 19:341–348.
  • PANDE AC, FELTNER DE, JEFFERSON JW et al: Efficacy of the novel anxiolytic pregabalin in social anxiety disorder: a placebo-controlled, multicenter study. I Chit. Psychopharmacul (2004) 24(2):141–149.
  • VAN AMERINGEN M, MANCINI C: Pharmacotherapy of social anxiety disorder at the turn of the millennium. Psychiatr. Clin. North Am. (2001) 4:783–802.
  • LOTT M, GREIST JH, JEFFERSON JWet al: Brofaromine for social phobia: a multicenter, placebo-contolled, double-blind study. I Clin. Psychopharmacol (1997) 17:255–260.
  • VERSIANI M, NARDI AE, MUNDIM FD, ALVES AB, LIEBOWITZ MR, AMREIN R: Pharmacotherapy of social phobia: a controlled study with moclobemide and phenelzine. BE Psychiatry (1992) 161:353–360.
  • VAN AMERINGEN M, MANCINI C, PIPE B, OAKMAN J, BENNETT M: An open trial of topiramate in generalized social phobia. Clin. Psychiatry (2004) 65(12):1674–1684.
  • SIMON NM, WORTHINGTON JJ, DOYLE AC, HOGE EA, KINRYS G, POLLACK MH: Levetiracetam for treatment of social anxiety disorder [poster]. Anxiety Disorders Association of America's 23' National Conference (2004) March 16–20, Miami FLD.
  • RICKELS K, MANGANO R, KHAN A: A double-blind, placebo-controlled study of a flexible dose of venlafaxine ER in adult outpatients with generalized social anxiety disorder. J. Clin. Psychopharmacol (2004) 24(5):488–496.
  • STEIN MB, POLLACK MH, BYSTRITSKY A, KELSEY JE, MANGANO RM: Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (2005) 177:280–288.
  • LIEBOWITZ MR, MANGANO RM, BRAD WEJN J, ASNIS G; SAD Study Group: A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J. Clin. Psychiatry (2005) 66:238–247.
  • WESTENBERG HG, STEIN DJ, YANG H, LI D, BARBATO LM: A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. I Clin. Psychopharmacol (2004) 24(1):49–55.
  • LIEBOWITZ MR, DEMARTINIS NA, WEIHS K et al: Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. I Clin. Psychiatry (2003) 64(7):785–792.
  • KOBAK KA, GREIST JH, JEFFERSON JW, KATZELNICK DJ: Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J. Chit. Psychopharmacol (2002) 22(3):257–262.
  • CLARK DM, EHLERS A, MCMANUS F et al:Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. ./. Consult. Clin. Psycho]. (2003) 71(6):1058–1067.
  • DAVIDSON JR, FOA EB, HUPPERT JD et al: Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia. Arch. Gen. Psychiatry (2004) 61(10):1005–1013.
  • KASPER S, STEIN DJ, LOFT H, NIL R: Escitalopram in the treatment of social anxiety disorder. BE J. Psychiatry (2005) 186:222–226.
  • Glaxo-SmithKline Corporation: Paxil (paroxetine hydrochloride) Prescribing Information: Last revised April 2004.
  • Glaxo-SmithKline Corporation: Paxil CR (paroxetine hydrochloride) Controlled-release tablets: Prescribing Information. Last revised April 2004.
  • WAGSTAFF AJ, CHEER SM, MATHESON AJ, ORMROD D, GOA KL: Paroxetine. An update of its use in psychiatric disorders in adults. Drugs (2002) 62(4):655–703.
  • LIEBOWITZ MR, STEIN MB, TANCER M, CARPENTER D, OAKES R, PITTS CD: A randomized, double-blind, fixed-dose comparison of paroxetine and placebo in the treatment of generalized social anxiety disorder. .1 Cliii. Psychiatry 63(1)66–74.
  • LEPOLA U, BERGTHOLDT B, ST LAMBERT J, DAVY KL, RUGGIERO L: Controlled-release paroxetine in the treatment of patients with social anxiety disorder. ./. Clin. Psychiatry (2004) 65(2):222–229.
  • LIEBOWITZ MR, GELENBERG AJ, MUNJACK D: Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch. Gen. Psychiatry (2005) 62:190–198.
  • LADER M, STENDER K, BURGER V, NIL R: Efficacy and tolerability of escitalopram in 12- and 24- week treatment of social anxiety disorder: randomized, double-blind, placebo-controlled, fixed-dose study. Depress. Anxiety (2004) 19:241–248.
  • STEIN DJ, VERSIANI M, HAIR T, KUMAR R: Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch. Gen. Psychiatry (2002) 59(12):1111–1118.
  • MENNIN DS, FRESCO DM, HEIMBERG RG, SCHNEIER FR, DAVIES SO, LIEBOWITZ MR: Screening for social anxiety disorder in the clinical setting: using the Liebowitz Social Anxiety Scale. .1 Anxiety Disord. (2002)16:661–673.
  • BALLENGER JC: Remission rates in patients with anxiety disorders treated with paroxetine. ./. Clin. Psychiatry (2004) 65:1696–1707.
  • CHAVIRA DA, STEIN MB: Recent developments in child and adolescent social phobia. Cur. Psychiatry Rep. (2000) 2:347–352.
  • STEIN MB: How shy is too shy? Lancet (1996) 347:1131–1132.
  • OTTO MW, POLLACK MH, MAKI KM et al: Childhood history of anxiety disorders among adults with social phobia: rates, correlates, and comparisons with patients with panic disorder. Depress. Anxiety (2001) 14:209–213.
  • PINE DS, COHEN P, GURLEY D, BROOKS J, MAY: The risk of early-adulthood anxiety and depressive disorders in adolescents with anxiety and depressive disorders. Arch. Gen. Psychiatry (1998) 55:56–64.
  • WAGNER KD, BERARD R, STEIN MB et al: A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch. Gen. Psychiatry (2004) 61(11):1153–1162.
  • •First placebo-controlled trial of an SSRI in a strict sample of youth SAD that demonstrates efficacy and safety in this age group.
  • FDA Public Health Advisory: October 15,2004.
  • TAYLOR S: Meta-analysis of cognitive-behavioral treatments for social phobia. Behav. Ther. Exp. Psychiatry (1996) 27:1–9.
  • BLANCO C, SCHNEIER FR, SCHMIDT A et al.: Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress. Anxieh,. (2003) 18(1):29–40.
  • ••Excellent review article on the efficacyof treatments in social anxiety disorder.
  • COOK RJ, SACKETT DL: The number needed to treat: a clinically useful measure of treatment effect. BM/(1995) 310:452–454.
  • ALTMAN DG, ANDERSEN PK: Calculating the number needed to treat for trials where the outcome is time to an event. BM/(1999) 319:1492–1495.
  • FAVA M: Weight gain and antidepressants.Clin. Psychiatry(2000) 61 (Suppl. 11):37–41.
  • FAVA M, JUDGE R, HOOG SL, NILSSON ME, KOKE SC: Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J. Clin. Psychiatry (2000) 61(11):863–867.
  • ROTHSCHILD AJ: Sexual side effects of antidepressants. j. Gila Psychiatry (2000) 61\(Suppl. 11):28–36.
  • ROSENBAUM JF, FAVA M, HOOG SL, ASCROFT RC, KREBS WB: Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol. Psychiatry (1999) 44:77–88.
  • GOLDEN RN: Efficacy and tolerability of controlled-release paroxetine. Psychopharmacul Bull. (2003) 37\(Suppl. 1):176–186.
  • American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders, edn 3 (1980): Washington DC: American Psychiatric Press, Washington DC, USA.

Website

  • Health Canada Endorsed Important Safety Information on Paxil (paroxetine) found at http://www:hc-sc.gc.ca/hpfb-dgpsaitpd-dptipaxil_hpc_e.html.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.